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Objective: The Edwards Duromedics valve (Baxter Healthcare Corp., Ed-
wards Division, Santa Ana, Calif.) was designed with a self-irrigating hinge
mechanism to reduce thromboembolic complications. After good initial
clinical results, distribution was suspended in 1988 after reports of valve
fracture after 20,000 valves had been implanted. The manufacturer con-
ducted extensive studies to improve the Edwards Duromedics and reintro-
duced a modified version, which is available as Edwards Tekna. The
purpose of the study was the evaluation of long-term results of the original
Edwards Duromedics that might be important for the current version, the
Edwards Tekna valve. Methods: A prospective clinical 10-year follow-up was
performed of 508 patients who underwent valve replacement with the
Edwards Duromedics valve in the aortic (n 5 268), mitral (n 5 183), and
aortic and mitral (n 5 56) position. Results: The perioperative mortality
rate was 6.9%; follow-up was 98% complete, comprising 3648 patient-years
for a mean follow-up of 86 months (range: 33 to 144 months). The actuarial
freedom from complications at the 10-year follow-up and the incidence rate
(percent per patient-year) were as follows: late mortality rate, 69.2% 6 2.4%
(3.5% per patient-year); thromboembolism, 90.7% 6 1.6% (0.96% per
patient-year); anticoagulation-related hemorrhage, 87.7% 6 1.7% (1.34%
per patient-year); prosthetic valve endocarditis, 96.7% 6 0.09% (0.38% per
patient-year); valve-related mortality rate, 89.3% 6 1.6% (1.21% per
patient-year); valve failure, 86.2% 6 1.85% (1.54% per patient-year); and
valve-related morbidity and mortality rate, 71.1% 6 2.3% (3.2% per
patient-year). Three leaflet escapes were observed (one lethal, two success-
ful reoperations; 99.1% 6 0.05% freedom, 0.08% per patient-year). All
patients functionally improved (86% in New York Heart Association classes
I and II), and incidence of anemia was insignificant. Conclusions: These
results confirm that the Edwards Duromedics valve shows excellent per-
formance concerning thromboembolism, hemolysis, and functional im-
provement and will serve as a reference for the last version, the Edwards
Tekna valve, where comparable long-term data are currently not available.
(J Thorac Cardiovasc Surg 1998;115:1121-9)
The Edwards Duromedics (Baxter HealthcareCorp., Edwards Division, Santa Ana, Calif.) pros-
thetic bileaflet heart valve was introduced into clin-
ical use in 1982; our institution (former II. Depart-
ment of Surgery, University of Vienna) was one of
the primary investigation centers, which started im-
plantation in 1983. After good initial clinical results,
two cases of leaflet escape were observed in our
institution in 1986; another 10 valve failures oc-
curred world-wide.1, 2 As a consequence, the valve
was withdrawn from the market in 1988 after ap-
proximately 20,000 valves had been implanted.
Since market suspension, Edwards CVS Division
has conducted extensive studies of the Edwards
Duromedics bileaflet valve. After these investiga-
tions, the prosthesis has been successfully modified
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and was reintroduced in 1990. The most important
improvements are an additional shock absorber in
the sewing ring and a more sophisticated quality
control of the material. The valve has been available
as the Edwards Tekna bileaflet valve since 1993.
This report summarizes experiences with the orig-
inal Edwards Duromedics valve in a prospective
clinical follow-up. We assert that clinical long-term
results will be comparable to the modified Edwards
Tekna bileaflet valve, especially with respect to
mechanical durability, thromboembolism, and pos-
sible hemolysis.
Material and methods
At the II Department of Surgery, University of Vienna,
between September 1983 and May 1988, a total of 564
Edwards Duromedics bileaflet prostheses were implanted
in 507 patients. Two hundred sixty-eight patients under-
went isolated aortic valve replacement (AVR), 183 pa-
tients underwent isolated mitral valve replacement
(MVR), and 56 patients underwent aortic and mitral
double valve replacement (DVR). To assure long-term
follow-up, only Austrian citizens or foreign residents in
Austria were included in the study protocol.
The cause of the valve disease was as follows: degener-
ated, calcified valves (51%); history of rheumatic disease
(30%); bacterial endocarditis (7%); and prosthetic rere-
placement (7%). In patients with no clear history of
rheumatic or other valve disease, the cause was classified
as unknown (5%). Seventy-seven (15%) patients had
undergone previous cardiac surgery, and 114 (22.5%)
patients had undergone additional procedures, mostly
coronary artery bypass operations. The different valve
sizes implanted in aortic and mitral position were as
follows: aortic dimension/number of implants (19/15, 21/
90, 23/109, 25/75, 27/32, 29/3), mitral dimensions/number
of implants (25/4, 27/37, 29/94, 31/88, 33/16). Further
perioperative patient data are given in Table I.
Operative technique and postoperative patient man-
agement. The standard cardiopulmonary bypass tech-
nique was used for valve implantations. Myocardial pro-
tection was achieved with moderate systemic hypothermia
(28° C), multiple-dose St. Thomas’ Hospital crystalloid
cardioplegia, and topical cooling with iced saline solution.
The prostheses were inserted with 2-0 polyester fiber
(Ti-Cron; Davis & Geck, Danbury, Conn.) pledget-armed
mattress sutures. Before surgery, patients received 5000
IU heparin therapy subcutaneously three times a day.
Permanent anticoagulation with phenprocoumon was
started on postoperative day 4. The target level of antico-
agulation was a thrombotest of 5% to 15% (Nycomed
Pharma, Oslo, Norway), representing an international
normalized ratio of 2.1 to 4.8.
Follow-up. The study protocol of the present study was
designed as a prospective follow-up, but after two in-
stances of leaflet escape from mitral valves, the prosthesis
was used only in the aortic position until it was withdrawn
from the market. Therefore the study group became
imbalanced. At 3 months and every year after surgery,
questionnaires were mailed to patients unless they were
seen in the outpatient department. From postoperative
year 3 onward, the questionnaires were completed and
signed by the patients with their general practitioners to
improve the accuracy of these forms. General practitio-
ners were also contacted to assess the accurate cause of
death in cases where a patient had died at home. Infor-
mation was available for 498 of the initial 507 patients;
thus follow-up was 98% complete. The cumulative patient
follow-up was 3647 patient-years with a mean observation
period of 86 months (years/months: AVR 1978/89, MVR
1286/84, DVR 382/82).
Definition of complications and consequences of mor-
bid events. Complications and consequences of morbid
events were defined according to the published guidelines
for reporting valve-related morbidity and mortality rates
after cardiac valvular operations.3 Because this follow-up
protocol was started in 1983 and already two follow-up
studies have been published according to the guidelines
dating from 1988, the present study was evaluated accord-
ing to the 1988 version.
Statistical analysis. Values are presented as the
mean 6 standard deviation. Actuarial estimates of morbid
events were calculated by the method of Kaplan-Meier
life-table analysis (product limit). Ninety-five percent con-
fidence limits for the distribution function were calculated
according to the Greenwood formula.4 The incidence of
complications for the 12-month intervals was determined
as the conditional probability of an event. The survivals of
an age- and sex-matched normal population were calcu-
lated from Austrian life-tables (Oesterreichisches Statis-
tisches Zentralamt, 1995). The Wilcoxon log rank test for
equality of survival curves was used to compare the
groups.
Results
Perioperative deaths. Thirty-five of 507 patients
died either within the first 30 days after the opera-
tion or during the hospitalization in which the
operation was performed, resulting in a periopera-
tive mortality rate of 6.9%. Of the perioperative
deaths, 36% of the patients had undergone addi-
tional procedures; 30.5% of the patients had under-
gone previous cardiac procedures. Fifteen patients
Table I. Patient characteristics
AVR MVR DVR Total
No. of patients 268 183 56 507
Mean age (yrs) 55 53 53 54
Male/female 1.8:1 1:1 1:1.3 1:1
Atrial fibrillation (%) 6 77 63 40
Systemic emboli* (%) 6.7 23 20 15
Operative mortality (%) 4.9 7.1 16 6.9
Previous cardiac surgery (%) 6.3 25 26.8 15
CABG or other additional
procedure (%)
33 17 14 22.5
CABG, Coronary artery bypass grafting.
*Percentage of patients with preoperative history of systemic embolism.
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died of low cardiac output syndrome; eight patients
died of a lethal myocardial infarction; five patients
died of septic complications including four patients
with acute endocarditis. In four patients, bleeding
was the major cause of death, which included two
ventricular ruptures. Three patients died of other
causes.
Late deaths. By the date of the last follow-up, 125
patients had died. The causes of late death were
valve-related in 44 patients. Among these patients,
thromboembolism occurred in four patients (two
valve thromboses, one cerebral and one mesenteric
embolism), and anticoagulation-related bleeding oc-
curred in eight patients. Five patients died of pros-
thetic valve endocarditis. One patient died of leaflet
escape in mitral position 8 years after the operation.
The autopsy showed the broken leaflet in the left
ventricular outflow tract. Ten patients died of other
cardiac diseases (myocardial infarction, arrhyth-
mia). Another 16 patients died suddenly of un-
known causes. Cardiac-related death from progres-
sive congestive heart failure was found in 50
patients; noncardiac-related death occurred in 31
patients. An overall survival rate of 69.2% 6 2.4%
(AVR 73.2% 6 3.1%; MVR 64.4% 6 4.1%; DVR
66.4% 6 8.0%) was calculated excluding perioper-
ative mortality rates, and 64.4% 6 2.3% (AVR
69.6% 6 3.1% versus MVR 59.84% 6 4.0% and
DVR 55.74% 6 7.5%; p 5 0.05) including periop-
erative mortality rates. The linearized rate of late
deaths after surgery was 3.5% per patient-year
(AVR 3.13%, MVR 4.19%, DVR 3.4%) excluding
perioperative mortality rates and 4.5% per patient-
year (AVR 3.79%, MVR 5.21%, DVR 5.76%)
including perioperative mortality rates. The survival
rate of an age- and sex-matched population accord-
ing to the Austrian life-tables was estimated (83%
after 120 months, Fig. 1).
Valve-related complications
Thromboembolism. Thirty-five patients sustained
a thromboembolic event. With the exception of the
four patients with lethal sequelae, ten patients had
embolic episodes that led to permanent neurologic
deficits. Overall freedom from thromboembolism,
including valve thrombosis, at 10 years was 90.7% 6
1.6% (AVR 90.9% 6 2.2%; MVR 89.4% 6 2.6%;
DVR 94.2% 6 4.1%; no significant difference), the
overall incidence of thromboembolism was 0.96%
per patient-year (AVR 0.87%; MVR 1.17%; DVR
0.52%; Fig. 2).
Anticoagulation-related hemorrhage. Forty-nine
patients had anticoagulation-related complications.
Gastrointestinal bleeding occurred in 15 patients
(one lethal); bleeding from the urogenital system
Fig. 1. Ten-year survival with and without operative mortality rates. The upper curve shows the survival
probability of the age- and sex-matched Austrian population. Incidences are on the lower part of the graph.
Bottom numbers represent months of observation and persons at risk. The solid line represents survival
control population; the dashed line represents survival without operative mortality rates; and the dotted line
represents survival with operative mortality rates.
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occurred in 15 patients; and cerebral bleeding oc-
curred in 9 patients (seven lethal). Ten patients
showed other bleeding. Six patients needed surgical
intervention to recover. The probability of freedom
from anticoagulation-related hemorrhage at 10
years was 87.7% 6 1.7% (AVR 84.4 6 2.6; MVR
91.0 6 2.3; DVR 86.0 6 6.0; no significant differ-
ence), the overall incidence of anticoagulation-re-
lated hemorrhage was 1.34% per patient-year (AVR
1.67%; MVR 1.09%; DVR 1.31%; Fig. 3).
Prosthetic valve endocarditis. Prosthetic valve
endocarditis developed in 14 patients. Five patients
died of this complication, and three patients under-
went successful reoperation. The probability of free-
dom from prosthetic valve endocarditis at 10 years
was 96.7% 6 0.09% (AVR 97.4% 6 1.05%; MVR
95.4% 6 1.7%; DVR 97.7% 6 2.3%; no significant
difference); the incidence of prosthetic valve endo-
carditis was 0.38% per patient-year (AVR 0.3%;
MVR 0.54%; DVR 0.26%).
Nonstructural dysfunction. All together 17 pa-
tients had nonstructural valve dysfunction; a hemo-
dynamically significant paravalvular leak was found
in 13 patients, of whom 5 patients had to undergo
reoperation, leaving 96.9% 6 0.09% (AVR 98.3%
6 0.84%; MVR 97.2% 6 1.4% versus DVR 88.5%
6 4.9%; p 5 0.01) free from this event (0.36% per
patient-year; AVR 0.2%; MVR 0.31%; DVR
1.31%). Two oversized valves necessitated reopera-
tion, and a high transvalvular gradient of 50 mm Hg
with normal leaflet mobility developed in one pa-
tient. In one mitral prosthesis the mural leaflet
failed to close intermittently. Although the patient
experienced a minor stroke, she did not agree to
undergo reoperation. The probability of freedom
from nonstructural valve dysfunction at 10 years was
95.8% 6 1.0% (AVR 97.1% 6 1.1%; MVR 96.4%
6 1.6% versus DVR 86.3% 6 5.3%; p 5 0.01), the
incidence of nonstructural valve dysfunction was
0.49% per patient-year (AVR 0.35%; MVR 0.39%;
DVR 1.57%).
Structural dysfunction. In two patients a leaflet
escape occurred in mitral position (one patient with
MVR, one with DVR); both patients underwent
successful reoperation, and the embolized leaflets
were removed.1 As mentioned earlier, one patient
died 8 years after the operation of leaflet escape in
the mitral position (MVR). The probability of free-
dom from structural valve dysfunction at 10 years
was 99.1% 6 0.05% (AVR 100%; MVR 98.2% 6
1.3%; DVR 97.7% 6 2.3%; no significant differ-
ence); the incidence of structural valve dysfunction
was 0.08% per patient-year (AVR 0%; MVR 0.16%;
DVR 0.26%).
Consequences of morbid events
Valve-related mortality rates. Forty-four patients
died of valve-related complications, as mentioned
earlier. The probability of freedom from valve-
Fig. 2. Event-free rate and yearly incidence of thromboembolic events after 120-month follow-up.
Incidences are on the lower part of the graph. Bottom numbers represent months of observation and
persons at risk; the solid line represents thromboembolic complications.
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related death at 10 years was 89.3% 6 1.6% (AVR
92.2% 6 1.8%; MVR 85.3% 6 3.0%; DVR 88.2%
6 5%; no significant difference); the incidence of
valve-related death was 1.21% per patient-year
(AVR 0.91%; MVR 1.63%; DVR 1.31%).
Permanent functional impairment. All in all there
were 19 cases of permanent functional impairment
caused either by stroke, by reduced stress tolerance
due to a paravalvular leak, or by impaired valve
function. Therefore 95.4% 6 1.3% (AVR 95.2% 6
1.4%; MVR 93.5% 6 3.6%; DVR 96.6% 6 1.5%;
no significant difference) of the patients were left
free of serious impairment (0.59% per patient-year;
AVR 0.56%; MVR 0.39%; DVR 0.78%).
Valve failure. Valve failure (1.54% per patient-
year; AVR 1.01%; MVR 1.94%; DVR 2.87%) oc-
curred in 56 patients, including 44 valve-related
deaths and 12 reoperations, leaving 86.2% 6 1.8%
of the patients free of event (AVR 91.4% 6 1.9%;
MVR 82.6% 6 3.2%; DVR 72.6% 6 7.5%; AVR
versus DVR, p 5 0.01; Fig. 4).
All valve-related mortality and morbidity rates. Sev-
enty-one (6 2) percent of the patients were free of
any valve-related complication (AVR 70.7% 6
3.3%; MVR 63.9% 6 4.1% and DVR 58.9% 6
8.4%; no significant difference); the linearized over-
all incidence was 3.26% per patient-year (AVR
3.24%; MVR 4.2%; DVR 4.19%; Fig. 4).
Hemolysis. Mechanical hemolysis was found in
all patients. It was detected by plasma hapto-
globolin, a very sensitive marker, which dropped
from 87 6 84 mg/dl after surgery to 19 6 25 mg/dl
(21.5 6 31 mg/dl, 14.8 6 15 mg/dl, and 20 6 23
mg/dl for AVR, MVR, and DVR, respectively) 1
year after surgery and remained depressed also at
the last laboratory follow-up after 4 years (15.6 6
46 mg/dl, 21.7 6 61 mg/dl, 10.7 6 27 mg/dl, and
7.7 6 5 mg/dl, all, AVR, MVR, and DVR, respec-
tively). Average plasma hemoglobin was 14.5 6
1.8 gm/L (14.9 6 1.6 gm/L, 14.1 6 2 gm/L, and
14 6 1.7 gm/L for AVR, MVR, and DVR, respec-
tively) 1 year and 14.4 6 2.0 gm/L (14.7 6 2 gm/L,
14.1 6 2.2 gm/L, and 14 6 1.6 gm/L for AVR,
MVR, and DVR, respectively) 4 years after the
operation. Plasma lactate dehydrogenase rose
from 230 6 97 IU/L to 359 6 151 IU/L (311 6 106
IU/L, 398 6 160 IU/L, and 460 6 171 IU/L for
AVR, MVR, and DVR, respectively) and 354 6
141 IU/L (304 6 108 IU/L, 390 6 140 IU/L, and
453 6 181 IU/L for AVR, MVR, and DVR,
respectively). Only one 75-year-old female patient
with DVR was left with clinically significant ane-
mia. This anemia was detected 9 years after
surgery. No other underlying disease was de-
tected, and the patient underwent successful re-
operation with two bioprostheses.
Fig. 3. Event-free rate and yearly incidence of anticoagulation-related hemorrhage after 120-month
follow-up. Incidences are on the lower part of the graph. Bottom numbers represent months of observation
and persons at risk; the solid line represents anticoagulation-related hemorrhage.
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Functional improvements. Of the 507 patients
for whom follow-up was completed, functional im-
provement was documented by a marked decrease
in New York Heart Association (NYHA) classifica-
tion, which improved from 3.1 6 0.7 after the
operation to 1.5 6 0.7 1 year after the operation.
This improvement was sustained over the follow-up
period, leaving 86% of the patients in NYHA classes
I and II (Fig. 5).
Discussion
Prosthetic valve replacement has remained the
most viable alternative for the treatment of severely
diseased heart valves.5-7 In this study, we summa-
rized our 14 years of experience with the Duromed-
ics Edwards bileaflet prosthesis. The authors are
aware that this report presents data that refer, to a
certain extent, to a historical valve because the
Duromedics Edwards bileaflet prosthesis was sus-
pended from the market in 1988. The reason to
present these data is twofold: Approximately 20,000
valves have been implanted, and the modified ver-
sion of this valve has been successfully introduced to
the market. Therefore the present results provide
important information on the long-term follow-up
of the Edwards Tekna valve because of similarities
in the design.
This cohort of patients has been followed up over
the past 14 years. In the 4- and 6-year follow-up, the
authors were able to show that mechanical hemoly-
sis was subclinical in all patients and that the risk of
thromboembolic complications and anticoagulation-
related hemorrhage was comparable to other me-
chanical valves.8, 9 In a case report, the successful
reoperation of two leaflet escapes in mitral position
was reported.1 In a Doppler sonographic 5-year
follow-up of a subgroup of 145 patients, not one
case of impaired left ventricular function was ob-
served. Paravalvular regurgitant jets were mild and
clinically insignificant; however, they were more
common in aortic than in mitral position.10 In a
second subgroup of this cohort, various mechanical
valves were evaluated with respect to their noise
level. The Duromedics Edwards prosthesis had the
loudest closing sound of all investigated valves.11
The present report confirms the excellent flow
characteristics, the data on hemolysis (anemia is
insignificantly low), and functional long-term im-
provement (86% of the patients are in NYHA
classes I and II). Average survival was 69%, includ-
ing 16 cases of sudden death. Each cause of sudden
death was confirmed by the respective cardiologist
or general practitioner who continuously treated
and followed the patient’s condition. The overall
freedom from thromboembolism was 91%, from
anticoagulation-related hemorrhage was 88%, and
from valve-related morbidity and death was 71%.
There were no significant differences between valve
Fig. 4. Event-free rate and yearly incidence of valve failure (solid line) and all valve-related morbidity and
mortality rates (dashed line) after 120-month follow-up. Incidences are on the lower part of the graph.
Bottom numbers represent months of observation and persons at risk.
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positions. However, the incidence of paravalvular
leaks was higher in patients with DVR compared
with patients with MVR or AVR alone (1.31%
versus 0.31% and 0.2% respectively, p 5 0.01). The
incidence of nonstructural dysfunction was signifi-
cantly higher in patients with DVR compared with
MVR and AVR (1.57% versus 0.39% and 0.35%,
respectively, p 5 0.01). The incidence of valve
failure was significantly lower in patients with AVR
compared with MVR and DVR (1.01% vs 1.94%
and 2.87% respectively, p 5 0.01).
Since the last report, the first patient of our
cohort died as the result of acute leaflet escape 8
years after MVR. Until 1996, Baxter Corporation
(personal communications to B. Podesser on patient
implant registry. Irvine, CA: Edwards CVS Division.
Baxter Healthcare Corporation, July 1997) reported
a total of 46 leaflet escapes; 67% of these patients
survived the event and underwent successful reop-
eration. According to the Baxter Corporation’s pa-
tient implant registry, which includes over 11,000
patients, the linearized incidence for structural dys-
function (leaflet escape) is 0.047% per patient-year
compared with 0.08% per patient-year in our co-
hort. This represents a freedom from leaflet escape
of 99.5% 6 0.08% or 99.1% 6 0.05%, respectively.
The authors believe that the size of the study
population (n 5 507) is the reason for this discrep-
ancy. A recommendation for an elective rereplace-
ment of the Edwards Duromedics valve, based on
these data, cannot be given, especially, when the
operative mortality rate of a redo operation in
mitral position is taken into account.12 This is in
contrast to the Bjo¨rk-Shiley CC prosthesis (Shiley,
Inc., Irvine, Calif.), where the actuarial incidence of
structural valve failure among a number of valves
with a certain diameter and date of production was
12.5% and prophylactic rereplacement for this se-
lected group was recommended.13
The data from Baudet and associates,14 reporting
an 8-year retrospective follow-up on the Edwards
Duromedics valve in 257 patients, show a higher rate
of survival: Overall actuarial survival was 90%;
survival in aortic position was 86%, in mitral posi-
tion was 95%, and in DVR was 89%. On the one
hand a lower overall incidence of thromboembolic
events (0.7% per patient-year) and anticoagulation-
related hemorrhage (0.95% per patient-year) might
be one reason for this discrepancy; on the other
hand the retrospective design of the study, where
Fig. 5. Physical ability graded according to the NYHA classes (1-4), preoperatively (time 5 0), 1 year
(time 5 l), 4 years (time 5 4,) and 10 years postoperatively (time 5 10). Bars indicate the relative frequency
for different valve positions.
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data were not accumulated continuously but 3 to 8
years after the implantation could be responsible for
the different observations. Finally, also the signifi-
cantly smaller number of patients must be men-
tioned.
The low incidence of thromboembolism and an-
ticoagulation-related hemorrhage in the present
study is also confirmed by the data from a meta-
analysis in patients with mechanical valve prosthe-
ses.15 In contrast, Fradet and associates6 showed in
a 10-year follow-up that only 65% of patients with
mechanical valves were free of thromboembolic
events versus 80% of patients with biologic valves.
However, their results might be partly explained by
the heterogeneous group of different mechanical
prostheses. This is especially important because the
curved areas of the Duromedics Edwards prosthesis
are known for their hydrodynamic superiority in
comparison to plane bileaflet valves.14 Finally, data
from a 10-year follow-up of another bileaflet valve,
the St. Jude Medical valve (St. Jude Medical, Inc.,
St. Paul, Minn.) are available. Aoyagi and associ-
ates5 present the data from 908 patients. Overall
survival including early death was higher than in our
cohort (81% for AVR, 80% for MVR, and 80% for
DVR), and the incidence of anticoagulation-related
hemorrhage was lower than in our cohort (0.4%,
0.3% and 0.5% for patients with AVR, MVR, and
DVR, respectively). But the incidence of thrombo-
embolism was higher than in our cohort (1% in
AVR, 1.1% in MVR, and 1.3 % in DVR). There
were almost no differences in the incidence of
prosthetic valve endocarditis and nonstructural dys-
function (0.4%, 0.03%, and 0.3%; 0.4%, 0.2%, and
0.2%; AVR, MVR, and DVR, respectively). No
case of structural dysfunction occurred whereas
three cases of leaflet escape were found in our
cohort. The freedom from valve-related death was
slightly higher (88%, 91%, and 84% for AVR,
MVR, and DVR, respectively); the freedom from all
complications was slightly lower than in our cohort
(75%, 74%, and 81% for AVR, MVR, and DVR,
respectively). Significant hemolysis occurred in eight
patients with St. Jude Medical valves in mitral
position; five of these patients died of the sequelae
of hemolysis. In contrast, no patient with a Edwards
Duromedics valve died because of hemolysis; one
patient with DVR had severe hemolysis and under-
went successful reoperation. Functionally, 98% of
the patients were in NYHA class I or II. All in all
these data from the St. Jude Medical valve suggest a
higher overall survival with lower incidence of anti-
coagulation-related hemorrhage and no structural
dysfunction but a higher incidence of thromboem-
bolic events and hemolysis.
The first data on the currently available Edwards
Tekna bileaflet valve are promising with respect to
valve-sound loudness and cavitation in comparison
with the original Edwards Duromedics and other
mechanical valves.16, 17 Also, the energy loss and
leakage volumes were low under static and in pul-
satile flow for the Edwards Tekna valve in compar-
ison to other mechanical valves.18
In summary, this 10-year follow-up confirms the
authors’ previous clinical findings with the Edwards
Duromedics bileaflet valve: (1) low morbidity as far
as thromboembolism, valve thrombosis, and hemo-
lysis are concerned; (2) long-lasting functional im-
provement; and (3) the possibility of late and lethal
leaflet escape. The structural failure of the Edwards
Duromedics valve led to readjustment of material
porosity and redesign; the currently available last
evolution of this valve, the Edwards Tekna, has the
superior properties of the original valve and the
improved requirements in material. The current
Edwards Tekna valve was introduced in 1993.
Therefore these data of the original Edwards Duro-
medics bileaflet valve are not just of historical
interest but are the only long-term results applicable
to the Edwards Tekna valve until updated results on
this valve become available.
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